{"id":54837,"date":"2026-04-14T16:48:07","date_gmt":"2026-04-14T16:48:07","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/54837\/"},"modified":"2026-04-14T16:48:07","modified_gmt":"2026-04-14T16:48:07","slug":"prelom-v-lecbe-rakoviny-slinivky-preparat-od-revmed-zdvojnasobil-dobu-preziti","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/54837\/","title":{"rendered":"P\u0159elom v l\u00e9\u010db\u011b rakoviny slinivky. Prepar\u00e1t od RevMed zdvojn\u00e1sobil dobu p\u0159e\u017eit\u00ed"},"content":{"rendered":"

Spole\u010dnost Revolution Medicines (RevMed) v pond\u011bl\u00ed p\u0159epsala historii onkologick\u00e9 l\u00e9\u010dby<\/a>. Jej\u00ed l\u00e9k daraxonrasib, pod\u00e1van\u00fd formou jedn\u00e9 pilulky denn\u011b, vyk\u00e1zal ve t\u0159et\u00ed f\u00e1zi klinick\u00fdch test\u016f u pacient\u016f s pokro\u010dilou rakovinou slinivky v\u00fdsledky, kter\u00e9 odborn\u00edci ozna\u010duj\u00ed za transformativn\u00ed. L\u00e9k t\u00e9m\u011b\u0159 zdvojn\u00e1sobil typickou dobu p\u0159e\u017eit\u00ed a o masivn\u00edch 60 procent sn\u00ed\u017eil riziko \u00famrt\u00ed ve srovn\u00e1n\u00ed s dosud standardn\u00ed chemoterapi\u00ed,\u00a0upozornil<\/a> server CNBC.\u00a0<\/p>\n

Konkr\u00e9tn\u00ed \u010d\u00edsla mluv\u00ed jasn\u011b: pacienti u\u017e\u00edvaj\u00edc\u00ed daraxonrasib \u017eili v pr\u016fm\u011bru 13,2 m\u011bs\u00edce, zat\u00edmco skupina l\u00e9\u010den\u00e1 chemoterapi\u00ed dos\u00e1hla pouze 6,7 m\u011bs\u00edce. Rozd\u00edl \u0161esti a p\u016fl m\u011bs\u00edce \u017eivota se v kontextu takto agresivn\u00edho onemocn\u011bn\u00ed pova\u017euje za bezprecedentn\u00ed. Rakovina slinivky m\u00e1 toti\u017e nejni\u017e\u0161\u00ed p\u011btiletou m\u00edru p\u0159e\u017eit\u00ed ze v\u0161ech hlavn\u00edch typ\u016f rakoviny \u2013 pouh\u00fdch 13 procent.\u00a0<\/p>\n

L\u00e9k daraxonrasib c\u00edl\u00ed na mutace genu RAS, kter\u00e9 funguj\u00ed jako motor r\u016fstu n\u00e1dor\u016f a vyskytuj\u00ed se p\u0159ibli\u017en\u011b u 90 procent v\u0161ech p\u0159\u00edpad\u016f rakoviny slinivky. \u201eTyto v\u00fdsledky zahajuj\u00ed novou \u00e9ru l\u00e9k\u016f c\u00edlen\u00fdch na RAS u rakoviny slinivky, kter\u00e1 byla dosud l\u00e9\u010dena v\u00fdhradn\u011b cytotoxickou nitro\u017eiln\u00ed chemoterapi\u00ed,\u201c uvedl v rozhovoru gener\u00e1ln\u00ed \u0159editel RevMed Mark Goldsmith. Podle n\u011bj jde o prvn\u00ed p\u0159\u00edpad, kdy l\u00e9k ve t\u0159et\u00ed f\u00e1zi test\u016f u tohoto onemocn\u011bn\u00ed vyk\u00e1zal prodlou\u017een\u00ed \u017eivota nad hranici jednoho roku.\u00a0<\/p>\n

Transforma\u010dn\u00ed prepar\u00e1t<\/p>\n

\u00dasp\u011bch test\u016f vyvolal siln\u00e9 emoce i u l\u00e9ka\u0159\u016f, kte\u0159\u00ed se na nich pod\u00edleli. Dr. Shubham Pant z onkologick\u00e9ho centra MD Anderson p\u0159i Texask\u00e9 univerzit\u011b popsal v\u00fdsledky jako \u201eskute\u010dn\u011b transforma\u010dn\u00ed\u201c. Pant, jen\u017e se \u00fa\u010dastnil \u0159ady p\u0159edchoz\u00edch studi\u00ed, kter\u00e9 skon\u010dily ne\u00fasp\u011bchem nebo prodlou\u017een\u00edm \u017eivota jen o t\u00fddny, serveru p\u0159iznal, \u017ee p\u0159i popisu dopad\u016f na sv\u00e9 pacienty poci\u0165uje hlubokou vd\u011b\u010dnost.\u00a0<\/p>\n

Zku\u0161enost s l\u00e9\u010dbou ned\u00e1vno ve\u0159ejn\u011b sd\u00edlel i b\u00fdval\u00fd americk\u00fd sen\u00e1tor Ben Sasse, kter\u00e9mu byla rakovina slinivky diagnostikov\u00e1na koncem lo\u0148sk\u00e9ho roku s perspektivou pouh\u00fdch n\u011bkolika m\u011bs\u00edc\u016f \u017eivota. Sasse uvedl, \u017ee po nasazen\u00ed daraxonrasibu se jeho n\u00e1dory zmen\u0161ily o 76 procent. Z\u00e1rove\u0148 ale popsal n\u00e1ro\u010dn\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky, zejm\u00e9na v\u00fdraznou vyr\u00e1\u017eku v obli\u010deji, kter\u00e1 doprov\u00e1z\u00ed l\u00e9\u010dbu u v\u011bt\u0161iny pacient\u016f. Podle l\u00e9ka\u0159\u016f je v\u0161ak tento projev zvl\u00e1dnuteln\u00fd pomoc\u00ed antibiotik nebo do\u010dasn\u00e9ho p\u0159eru\u0161en\u00ed pod\u00e1v\u00e1n\u00ed l\u00e9ku.\u00a0<\/p>\n

Burza na zpr\u00e1vu zareagovala okam\u017eit\u011b. Akcie spole\u010dnosti Revolution Medicines v pond\u011bl\u00ed ve\u010der vysko\u010dily o v\u00edce ne\u017e 30 procent a jejich hodnota za posledn\u00ed rok vzrostla o 274 procent. Tr\u017en\u00ed kapitalizace firmy tak p\u0159es\u00e1hla 26 miliard dolar\u016f. A\u010dkoliv je spole\u010dnost dlouhodob\u011b vn\u00edm\u00e1na jako atraktivn\u00ed c\u00edl pro akvizici, \u0161\u00e9f Mark Goldsmith zd\u016fraznil, \u017ee prioritou je nyn\u00ed p\u0159\u00edprava na schv\u00e1len\u00ed a uveden\u00ed l\u00e9ku na trh, nikoliv jeho prodej.\u00a0<\/p>\n

Kritick\u00e1 situace v \u010cesku<\/p>\n

Situace v \u010cesku je v kontextu rakoviny slinivky alarmuj\u00edc\u00ed. Od sametov\u00e9 revoluce do\u0161lo k dramatick\u00e9mu n\u00e1r\u016fstu po\u010dtu nemocn\u00fdch o 450 procent, varoval ji\u017e d\u0159\u00edve web e15<\/a>.\u00a0Zat\u00edmco v roce 1990 trp\u011blo t\u00edmto typem n\u00e1doru necel\u00fdch osm lid\u00ed na sto tis\u00edc obyvatel, v roce 2022 to bylo ji\u017e p\u0159es 36 osob. V\u00fdskyt onemocn\u011bn\u00ed v tuzemsku je tak o 23 procent nad pr\u016fm\u011brem Evropsk\u00e9 unie a jde o nejrychleji rostouc\u00ed typ n\u00e1dorov\u00e9ho onemocn\u011bn\u00ed v zemi.\u00a0<\/p>\n

Progn\u00f3za pro \u010desk\u00e9 pacienty p\u0159itom z\u016fst\u00e1v\u00e1 nep\u0159\u00edzniv\u00e1, u 87 procent z nich nen\u00ed v\u00fdhled na vyl\u00e9\u010den\u00ed pozitivn\u00ed. Hlavn\u00edm vin\u00edkem je pozdn\u00ed diagnostika, nebo\u0165 pro tuto agresivn\u00ed chorobu zat\u00edm neexistuje \u00fa\u010dinn\u00fd plo\u0161n\u00fd screeningov\u00fd program. \u00damrtnost se od roku 1990 t\u00e9m\u011b\u0159 zdvojn\u00e1sobila a \u010cesk\u00e1 onkologick\u00e1 spole\u010dnost odhaduje, \u017ee v roce 2030 se rakovina stane nej\u010dast\u011bj\u0161\u00ed p\u0159\u00ed\u010dinou \u00famrt\u00ed v \u010cesku.\u00a0<\/p>\n

L\u00e9ka\u0159i p\u0159esnou p\u0159\u00ed\u010dinu takto strm\u00e9ho n\u00e1r\u016fstu neznaj\u00ed. Krom\u011b tradi\u010dn\u00edch faktor\u016f, jako jsou kou\u0159en\u00ed \u010di alkohol, zmi\u0148uj\u00ed i stres a zne\u010di\u0161t\u011bn\u00ed \u017eivotn\u00edho prost\u0159ed\u00ed. St\u00e1t do onkologick\u00e9 p\u00e9\u010de nyn\u00ed masivn\u011b investuje, nap\u0159\u00edklad skrze v\u00fdstavbu nov\u00e9ho centra ve Fakultn\u00ed nemocnici v Motole.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Spole\u010dnost Revolution Medicines (RevMed) v pond\u011bl\u00ed p\u0159epsala historii onkologick\u00e9 l\u00e9\u010dby. Jej\u00ed l\u00e9k daraxonrasib, pod\u00e1van\u00fd formou jedn\u00e9 pilulky denn\u011b,…\n","protected":false},"author":2,"featured_media":54838,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[19657,67,68,42,19656,571,19660,19658,665,19655,2782,19659],"class_list":{"0":"post-54837","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-byznys","8":"tag-ben-sasse","9":"tag-business","10":"tag-byznys","11":"tag-cesko","12":"tag-chemoterapie","13":"tag-evropska-unie","14":"tag-fakultni-nemocnice-v-motole","15":"tag-mark-goldsmith","16":"tag-nemoc","17":"tag-rakovina-slinivky","18":"tag-sametova-revoluce","19":"tag-univerzita-pardubice"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116404086620299366","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/54837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=54837"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/54837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/54838"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=54837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=54837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=54837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}